Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-024-08503-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Putting Crohn's Disease on the MAP: Potential Contribution of a "Stealth Pathogen".
Dig Dis Sci
July 2024
AmsterdamUMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Meibergdreef 69-71, Amsterdam, The Netherlands.
Acceptability Criteria of Precision Medicine: Lessons From Patients' Experiences With the GUIDE-IBD Trial Regarding the Use of Mobile Health Technology.
Crohns Colitis 360
October 2023
Institute for Experimental Medicine, Medical Ethics Working Group, Kiel University, Kiel, Germany.
Background: Research about mobile health technologies for inflammatory bowel diseases reveals that these devices are mainly used to predict or self-report disease activity. However, in the near future these tools can be used to integrate large data sets into machine learning for the development of personalized treatment algorithms. The impact of these technologies on patients' well-being and daily lives has not yet been investigated.
View Article and Find Full Text PDFReview article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
Aliment Pharmacol Ther
June 2023
Department of Gastroenterology and Hepatology, University Hospital Leuven, Leuven, Belgium.
Background: Sarcopenia, a loss of skeletal muscle mass or function, affects up to 50% of patients with inflammatory bowel disease (IBD) and is associated with poor clinical outcomes including increased hospitalizations, need for surgery and post-operative complications. Despite the high prevalence and clinical significance of sarcopenia in patients with IBD, few patients undergo routine muscle evaluation.
Aim: The goal of this study was to review the mechanisms of sarcopenia in patients with IBD and understand novel modalities to assess and treat impaired muscle mass or function.
The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics.
Crohns Colitis 360
July 2021
Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
The costs associated with biologic therapy in immune-mediated diseases, including inflammatory bowel disease has steadily increased since their introduction over 2 decades ago. The introduction of biosimilars has the promise of cost savings and putting reimbursement pressure on future market entries. However, the interpretation of evidence to support the use of biosimilars either as first line or as part of a nonmedical switch strategy is not straight forward due to low to very low-quality evidence.
View Article and Find Full Text PDFDiagnostic challenge between Crohn's disease and intestinal tuberculosis in chronic diarrhea with ulcerated jejunal stenosis: a case report.
Rev Gastroenterol Peru
October 2021
Department of Internal Medicine, Section of Gastroenterology and Endoscopy, Universidad Javeriana. Bogotá, Colombia; Gastroenterology and Endoscopy Unit, Hospital Universitario San Ignacio. Bogotá, Colombia.
Intestinal tuberculosis and Crohn's disease are a diagnostic challenge because of the clinical, radiological and endoscopic similarity. The histological and microbiological findings are positive in less than 50%, which delays the correct treatment, putting the patient at risk. We reported a 34-year-old immunocompetent patient with 4 years of malabsorptive diarrhea, weight loss, nocturnal diaphoresis, abdominal pain and an ulcer with stenosis in the jejunum was found; she received empirical anti- tuberculosis treatment with clinical improvement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!